Deletions lead to inactivation of tumor suppression proteins, such as PTEN (antagonist of the PI3K/Akt pathway), retinoblastoma protein (pRb), cyclin-dependent kinase inhibitors (CKI), p53, etc. Protein p53 is probably the most studied in cancer research and is known as the guardian of genome. This evidence concerns the gene AKT1 and cancer.